John Bluth | SVP, IR and Corporate Communications |
Jon Stonehouse | Chief Executive Officer |
Anthony Doyle | Chief Financial Officer |
Dr. Bill Sheridan | Chief Medical Officer |
Charlie Gayer | Chief Commercial Officer |
Dr. Helen Thackray | Chief R&D Officer |
Ken Cacciatore | Cowen and Company |
Jon Wolleben | JMP Securities |
Chris Raymond | Piper Sandler |
Daniel Wolle | JPMorgan |
Serge Belanger | Needham & Co. LLC |
Gena Wang | Barclays Capital Inc. |
Brian Abrahams | RBC Capital Markets |
Liisa Bayko | Evercore ISI |
Justin Kim | Oppenheimer |
Good day, and thank you for standing by. Welcome to the BioCryst Pharmaceuticals First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] I would now like to hand the conference over to your speaker today, John Bluth, Head of Investor Relations at BioCryst.
Thanks, Daniel.